T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024
LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the fourth quarter and full year 2023 and business updates after market close on Thursday, February 15, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Related news for (TTOO)
- T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
- T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor
- T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally
- T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
- T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens